Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Jaeger

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
Haematologica|July 29, 2017
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trialsJennifer R Brown, Javid Moslehi, Susan O'Brien, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 27, 2019
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic LeukemiaThomas J Kipps, Graeme Fraser, Steven E Coutre, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 26, 2018
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, et al.
Cancers|February 15, 2022
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL StudyJosée M Zijlstra, George Follows, Rene-Olivier Casasnovas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2020
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III StudyArnon P Kater, Jenny Qun Wu, Thomas Kipps, et al.
Haematologica|January 18, 2015
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic LeukemiaCarol Moreno, Marco Montillo, Panayiotis Panayiotidis, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.
Acta Oncologica (Stockholm, Sweden)|April 18, 2019
Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based studyMagdalena Neuhauser, Thomas Roetzer, Stefan Oberndorfer, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
Haematologica|July 29, 2017
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trialsJennifer R Brown, Javid Moslehi, Susan O'Brien, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 27, 2019
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic LeukemiaThomas J Kipps, Graeme Fraser, Steven E Coutre, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 26, 2018
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, et al.
Cancers|February 15, 2022
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL StudyJosée M Zijlstra, George Follows, Rene-Olivier Casasnovas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2020
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III StudyArnon P Kater, Jenny Qun Wu, Thomas Kipps, et al.
Haematologica|January 18, 2015
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic LeukemiaCarol Moreno, Marco Montillo, Panayiotis Panayiotidis, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.
Acta Oncologica (Stockholm, Sweden)|April 18, 2019
Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based studyMagdalena Neuhauser, Thomas Roetzer, Stefan Oberndorfer, et al.
Pageof 11